Study of Retinopathy of Prematurity Frequency, Risk Factors, and Treatment in Premature Infants Over 1500 Grams or 33 Weeks Gestation in Turkey

What this Trial Is About

Researchers are studying preterm infants in Turkey who are being screened for retinopathy of prematurity ROP between August 1, 2023, and August 1, 2024. The study focuses on infants with a birth weight over 1500 grams or gestational age of 33 weeks or more. It aims to determine how often ROP occurs, identify severe cases requiring treatment, and evaluate risk factors contributing to ROP development. Certified neonatologists from 94 neonatal intensive care units across Turkey collect data using electronic questionnaires. Medical records of retinal exams are reviewed, and detailed risk factors like gestational age, birth weight, steroid therapy, infections, respiratory issues, and feeding methods are recorded. The study also includes infants of refugees to assess ROP incidence within this group. Ophthalmologic exams continue until full retinal vascularization, with disease stages and treatments tracked according to international guidelines. Participants are monitored throughout their NICU stay with data pooled for analysis. Researchers assess the incidence of ROP, evaluate treatment outcomes such as laser photocoagulation and anti-VEGF therapy, and study the impact of various clinical factors on ROP development. The primary outcome is the incidence of ROP within 12 months, with secondary outcomes addressing specific risk factors and treatment methods.

Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey.